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Background: Clostridium difficile infections caused by the NAP1/B1/027 strain are more severe,
difficult to treat, and frequently associated with relapses.
Methods: A case–control study was designed to examine a  C. difficile infection (CDI) outbreak
over a  12-month period in a  Mexican hospital. The diagnosis of toxigenic CDI was confirmed
by  real-time polymerase chain reaction, PCR (Cepheid Xpert C. difficile/Epi).
Results: During the study period, 288 adult patients were evaluated and 79  (27.4%) patients
had confirmed CDI (PCR positive). C. difficile strain NAP1/B1/027 was identified in 31  (39%) of
the  patients with confirmed CDI (240 controls were included). Significant risk factors for CDI
included any underlying disease (p < 0.001), prior hospitalization (p < 0.001), and antibiotic
(p  < 0.050) or steroid (p < 0.001) use. Laboratory abnormalities included leukocytosis (p < 0.001)
and low serum albumin levels (p < 0.002). Attributable mortality was 5%. Relapses occurred
in  10% of patients. Risk factors for C. difficile NAP1/B1/027 strain infections included prior
use  of quinolones (p  < 0.03).
Risk factors for CDI caused by non-027 strains included chronic cardiac disease (p < 0.05),
chronic  renal disease (p < 0.009), and elevated serum creatinine levels (p <  0.003). Deaths and
relapses were most frequent in the  027 group (10% and 19%, respectively).
Conclusions: C. difficile NAP1/BI/027 strain and non-027 strains are established pathogens in
our hospital. Accordingly, surveillance of C. difficile infections is now part of our nosocomial
prevention program.
© 2015 Elsevier Editora Ltda. All rights reserved.
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Introduction
Clostridium difficile infections (CDI) are the leading world-
wide cause of healthcare-associated diarrhea and in some
countries CDI surpass all other healthcare-associated infec-
tions (HCAI).1 A  recent prevalence survey of HCAI conducted
across 183 hospitals determined that C. difficile was  the most
frequently reported infectious agent, responsible for 12.1% of
all HCAI.1
In the United States of America (USA) during 2011, 15,461
CDI cases were reported with 24.2% of cases having an  onset
during hospitalization. Incident CDI cases were estimated
to be >450,000 with an  estimated >29,000 deaths.2 However,
the emergence of the C. difficile NAP1/B1/027 strain in 2000
changed the morbidity and mortality rates associated with
CDI.3,4
Since 2004, the role of other emergent C. difficile strains
causing human disease has expanded. These strains are
derived from 39 different ribotypes and some C. difficile strains
have been found to be toxin A-negative but toxin B-positive,5
and 027 strain was the  second most common isolate respon-
sible for CDI.6 Ribotype 078 was  reported to have an  increased
prevalence,7 and ribotype 244 seems to  cause more  severe
disease with higher mortality rates than rates associated
with ribotype 027.8,9 The prevalence of other ribotypes now
appears to surpass that of 027, including ribotypes 037, 018,
and 078.10–12
Epidemiologic research of CDI resulting from infections
with diverse C. difficile strains, including strain NAP1/B1/027
in developing countries, is expanding and includes data
regarding hospital epidemiology, clonal spread, and dissem-
ination across the respective countries.13–16
The present study reports on a 12-month evaluation of a
CDI outbreak caused by different C. difficile strains including
the NAP1/BI/027 strain.
Methods
Setting,  study  design,  and  study  population
The outbreak described in  this report occurred at the Hospital
Civil de Guadalajara Fray Antonio Alcalde, an  899-bed tertiary
care teaching hospital located in  the  city of Guadalajara, the
second largest city in Mexico.
This was a  case–control study of adult patients with
hospital-onset CDI presenting between December 2013 and
December 2014. During the study period 288 adult patients
were evaluated and all patients had diarrhea defined as  the
passage of ≥3 unformed stools (Bristol scale type 5–7) within
24 or 48 h after admission.17 Case patients were defined as
those with a first episode of nosocomial CDI.
Clostridium  difficile  toxin  identification
Starting in April 2014, all stool samples were tested for
C. difficile toxins using real-time polymerase chain reaction
(PCR) (Cepheid Xpert C. difficile/Epi, Cepheid, Sunnyvale CA)
to identify toxin-producing C. difficile strains, including strain
NAP1/B1/027. Prior to the availability of PCR-based diagnostic
approaches all diarrhea specimens were tested by enzyme
immunoassay (Meridian Bioscience, Cincinnati, OH, USA). All
positive specimens were saved for future testing. All stool
specimens were stored at 4◦ C for five days, and then frozen
at −70◦ C. After PCR retesting, only positive samples were
included in the final analysis.
Control  patients
Patients without diarrhea or a positive CDI test were selected
at the same time and ward that CDI patients were identi-
fied. Control patients were randomly selected across the study
period. Control patients were matched to case patients at a 3:1
ratio.
Definitions
Previous hospitalization was  defined as a hospital stay six
weeks prior to the onset of diarrhea. Recent antibiotic therapy
and steroid use were defined as exposure to these medicines
six weeks prior to diarrhea onset.
Clinical  severity  score  assessment  and  outcome
Patients were clinically evaluated for disease severity using
the SHEA/IDSA definitions of mild, moderate, or severe dis-
ease. Serum creatinine levels were included in the definition
of severe disease.18 In addition, age >60 years, fever >38.3 ◦C,
and a WBC  count >15,000 were used to  further define clinically
severe disease.19 Patients with >2 findings were considered to
have severe disease.
A  poor outcome was  defined as  death within 14 days after
CDI diagnosis. Favorable outcome was defined by survival 14
days after CDI  diagnosis. Relapse was defined as  a  second
episode of diarrhea after adequate response to therapy.
Therapy  and  follow-up
Therapy for CDI was administered for 10 days after an ade-
quate response to treatment was achieved (defined as  a  50%
reduction of loose stools after 24 h of therapy, continuous
reduction after 48 h of treatment, and no diarrhea after 72  h
of treatment). All patients discharged where followed via tele-
phone every 30 days.
Statistical  analysis
The data generated were coded, entered, validated, and ana-
lyzed using the Statistical Package for Social Science (SPSS),
version 22.0. Univariate analyses were used to describe sig-
nificant variables among cases and controls and among
individuals infected with strain 027 and individuals infected
with non-027 strains. P-values were calculated using the Chi-
squared test or the  Fisher’s exact test for categorical variables
and the  Student’s t-test or Wilcoxon rank-sum test for con-
tinuous variables. A  p-value ≤0.05 was considered statistically
significant. Multivariate analysis: logistic regression analysis
was carried out considering CDI as  dependent variable and
clinical and demographic data as independent variables.
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Table 1 – Characteristics of CDI patients and controls, severity, outcomes, relapses, and clinical aspects of patients
infected with 027  and non-027 strains.
Parameters CDI patients (n  = 79)
n (%)
Controls (n =  240)
n (%)
p-value 027 strain (n = 31)
n (%)
Non-027 strain
(n = 48)
n  (%)
p-value
Age (y)
18–30 23 (29.1) 62  (25.8) 0.28 7 (23) 16  (34) 0.22
31–50 24 (30.4) 88  (36.7) 0.15 11  (35) 13  (27) 0.29
51–65 21 (26.6) 53  (22.1) 0.20 10  (32) 12  (25) 0.32
>65 11 (13.9) 37 (15.4) 0.38 3 (10) 7 (14) 0.39
Gender
Male 51 (64.5) 148 (61.7) 0.32 21  (67.7) 30  (62.5) 0.40
Female 28 (35.5) 92  (38.3) 0.32 10  (32.3) 18  (37.5) 0.40
Underlying disease
Any 73 (92.4) 170 (70.8) <0.001 27  (87.1) 46  (95.6) 0.15
Malignancy 11 (13.9) 18  (7.5) 0.142 6 (19.3) 5 (10.4) 0.21
Diabetes mellitus 20 (25.3) 51  (21.3) 0.27 5 (16.1) 15  (31.3) 0.10
Chronic cardiac disease 22 (27.8) 49  (20.4) 0.112 5 (16.1) 17  (35.4) 0.05
Chronic hepatic disease 2 (2.5) 5  (2.0) 0.55 0 2 (4.2) 0.36
Previous episode of
pneumonia
16 (20.2) 16  (6.7) 0.005 5 (16.1) 11  (22.9) 0.33
Chronic renal disease 23 (29.1) 43  (17.9) 0.027 4 (12.9) 19  (39.6) 0.009
Healthcare-associated exposure
Prior hospitalization 43 (54.4) 57  (23.8) <0.001 20  (64.5) 23  (47.9) 0.11
Prior surgery 44 (55.7) 117 (48.8) 0.173 17  (62.9) 27  (56.3) 0.54
Prior antibiotics
Any 58 (73.4) 150 (62.5) 0.050 23  (74.2) 35  (72.9) 0.55
Betalactams 43 (54.4) 108 (45) 0.155 17  (54.8) 30  (62.5) 0.32
Quinolones 16 (20.3) 31  (12.9) 0.142 9 (39.13) 5 (10.4) 0.03
Clindamycin 10 (12.7) 38  (15.8) 0.313 4 (17.39) 6 (12.5) 0.60
Prior use of acid suppressing medication
Proton pump inhibitors 67 (84.8) 192 (80.0) 0.21 25  (80.65) 42  (87.5) 0.30
H2 blocker 5 (6.3) 18  (7.5) 0.47 1 (3.23) 4 (8.3) 0.34
Prior use of steroids 17 (21.5) 16(6.7) <0.001 8 (25.8) 9 (18.8) 0.31
White blood cells count
>12,000/mm3
37 (46.8) 63  (26.3) <0.001 15  (48.4) 22  (45.8) 0.50
Serum creatinine
≥1.5 mg/dl
22 (27.8) 53  (22.1) 0.20 3 (9.7) 19  (39.6) 0.003
Serum albumin <3  g  dl 46 (58.2) 91  (37.9) <0.002 18  (58.1) 28  (58.3) 0.58
Initial Clinical Severity
Score ≥2
69 (87.3) – –  28  (90) 41  (85) 0.39
Outcome
Poor/death 4 (5) – –  3 (10) 1 (2) 0.16
Good/cured 75 (95) – –  28  (90) 47  (98) 0.16
Relapses 8 (10) – –  6 (19) 2 (4) 0.03
Results
Study  population
The age range of CDI patients and controls were similar
(Table 1). Patients >65 years of age were the minority in both
groups (Table 1). There was no gender difference between
cases and controls; however, males were more frequently
affected with CDI than females (Table 1). The presence of
any underlying disease was an important risk factor for
acquiring CDI, especially a previous episode of pneumonia
or the presence of chronic renal disease (Table 1). Additional
risk factors associated with CDI included prior hospitaliza-
tion, antibiotic or steroid use, and elevated white blood cell
counts (>12,000/mm3) combined with low serum albumin lev-
els (<3 g/dl) (Table 1). Four (5%) patients died in the CDI group
and 8 (10%) relapsed (Table 1). The incidence of CDI was  1.7
per 1000 discharges.
NAP1/B1/027  infections
Strain NAP1/B1/027 was identified in 31 (39%) patients with
CDI. There were some differences between CDI resulting from
infections with strain 027 and non-027 strains. The presence
of chronic cardiac disease and chronic renal disease were
found to be significantly more  frequent in the non-027 group
(Table 1). Although both groups had a  similar initial severity
score, more  deaths and relapses were associated with  strain
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Table 2 – Multivariate logistic regression analysis of risk
factors for CDI.
Risk factor OR CI 95% p-value
White blood cells count
>12,000/mm3
2.541 1.414–4.567 0.002
Prior hospitalization 4.029 2.240–7.246 0.001
Serum Albumin <3 g dl 2.026 1.138–3.608 0.016
Previous episode of
pneumonia
4.251 1.848–9.779 0.001
Prior use of steroids 5.077 2.203–11.698 0.001
027 infections (Table 1). Additional risk factors associated
with 027 and non-027 infections were prior use of quinolone
and abnormal serum creatinine level (>1.5 mg/dl), respectively
(Table 1).
Logistic regression analysis included the  significant risk
factors for CDI  prior use of steroids, a  previous episode of
pneumonia, and prior hospitalization (Table 2). Also identi-
fied abnormal white blood cell count and low serum albumin
levels as independent risk factors for acquiring CDI (Table 2).
Discussion
The CDI outbreak described in this report occurred following
introduction of the C. difficile 027 strain into our hospital by a
patient diagnosed in  December 2013. This individual had had
multiple healthcare contacts in  the USA (including several due
to diarrhea) prior to being admitted to our neurosurgical ward.
Introduction of C. difficile into a  hospital will usually develop
into an outbreak and previous studies have documented out-
breaks following detection of strain 027.3,4,20
Other Latin American countries from Central and South
America have now described the presence and dissemina-
tion of C. difficile.15,21 The C. difficile dissemination pattern
seen in Mexico was similar to that described in  hospitals in
the USA and Canada, but different from that of the Euro-
pean Union where C. difficile 027 is not yet as  prevalent. The
appearance, establishment, and dissemination of C. difficile in
Mexico seemed to occur in  large referral hospitals where a  high
percentage of patients admitted had multiple risk factors for
CDI.14,22
The presence of a serious underlying disease is  a  frequent
risk factor for the  development of CDI23 and the presence
of any underlying illness (particularly a  previous episode of
pneumonia) was a  significant risk factor in patients compared
to controls.
In our population, community acquired pneumonia was
diagnosed most frequently in older patients with comorbidi-
ties including chronic obstructive pulmonary disease. These
patients typically had multiple previous healthcare exposures
including prior hospitalizations allowing for a greater prob-
ability of acquiring C. difficile. Because current guidelines of
our hospital recommend administration of quinolones as
empiric treatment for pneumonia24 this patient group had
been exposed to this drug.
A  frequent risk factor in our study included patients with
chronic renal disease. Since our hospital is a regional center
for the diagnosis and care of patients in  need  of renal replace-
ment therapy or a renal transplant it is responsible for a  large
population that is  affected by this underlying illness.25 Similar
to patients with other chronic diseases, patients with chronic
renal disease have multiple healthcare contacts (including
dialysis) and have multiple previous antibiotic exposures
due to empiric or definitive treatment of different infectious
diseases complications, including peritonitis resulting from
peritoneal dialysis. Concomitant administration of steroids
occurs frequently when patients have serious comorbidities
and need assistance in the treatment of various complica-
tions.
The clinical features found in our CDI patients included
an  increased white blood cell count, elevated serum creati-
nine and reduced serum albumin levels. These findings are
the basis for most clinical prediction rules used today.18,19,26–29
Patients presenting with severe CDI typically were older and
had an  increased number of bowel movements, had a his-
tory of systemic antibiotic use, and presented with fever,
abdominal distention, abnormal respiratory rate, abnormal
level of C-reactive protein, prior episodes of CDI, increased
white blood cell count, elevated serum creatinine level, and
low serum albumin level.18,19,26–29 Using these clinical predic-
tion rules most of our patients had severe CDI.
The use of clinical prediction rules in CDI  are also used
to determine individuals at risk of having poor outcomes or
a  relapse.28,30–34 The most prominent factor predictive of a
poor outcome or relapse among CDI patients described in  this
report was infection with strain 02735 and chronic renal dis-
ease.
After eliminating confounders, independent risk factors for
CDI included prior use of steroids, previous episodes of pneu-
monia, and prior hospitalizations (Table 2). The epidemiology
of C. difficile infections is  constantly changing and probably
explains some of the  differences found in our study compared
with previous observations made in Mexico.14,22,36
The diagnosis of CDI was primarily carried out using a com-
mercial PCR kit,  a test that has high sensitivity and specificity
but with several limitations, including the inability of this test
to identify emergent C. difficile variants.9,37,38
The choice for initial empirical therapy in our study
consisted of metronidazole. Other therapeutic choices
included administration of oral vancomycin as  opposed to
intravenous administration combined with either intravenous
metronidazole or intravenous tigecycline based on individual
response to oral metronidazole.39,40
In an  effort to  control the outbreak our intervention pro-
gram focused on identifying CDI cases as  quickly as possible,
providing early treatment, isolating CDI cases in a  dedicated
ward, and restricting all quinolone use.41–43 The presence of
a  disease such as CDI that is  transmitted via oral-fecal con-
tamination prompted us  to reevaluate patient hand washing
practices prior to each meal or the intake of oral medication,
in addition to assessing hand washing practices of the staff
assigned to help feed  patients. This resulted in  the implemen-
tation of an aggressive patient hand washing campaign.
All patients discharged after an episode of CDI received
careful instructions on how to proceed should a  relapse
occur.44 The instructions included a  description of some of
the symptoms that may  present during a relapse, where to get
medical attention, and what to inform healthcare personnel
on arrival to clinics.
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The present study had several limitations including the
lack of C. difficile cultures to enable typing, limited use of a
computed tomography scan for abdominal radiographic imag-
ing prior to  colonoscopy, colonoscopy for diagnosis of CDI,
follow-up PCR testing was used only in select patients,45 and
no autopsies were performed.
In conclusion, the control of CDI in our hospital now rep-
resents a constant challenge. The control of CDI in a hospital
like ours should include a  tailored strategy designed to iden-
tify cases of CDI as rapidly as possible. This study represents
the first description of an extended CDI outbreak caused by
diverse C. difficile strains including the NAP1/B1/027 strain in
a Mexican hospital.
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